Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing and is set to launch in China in 2026
Regulatory Filings Classification · 95% confidence The document is a press release issued by Cinclus Pharma regarding the inclusion of their drug, linaprazan glurate, in China's National Reimbursement Drug List. It contains corporate news, contact information, and a disclaimer stating it is published pursuant to the EU Market Abuse Regulation. Since it is a general corporate announcement that does not fit into specific categories like earnings or M&A, and serves as a regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-12-08 English
Cinclus Pharma rekryterar Magnus Christensen som ny CFO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CFO (Magnus Christensen) and an interim CFO (Patrik Norgren) at Cinclus Pharma. This falls under the category of board or management changes. Although the document includes a link to a PDF version, the content itself is a direct announcement of management personnel changes, which fits the 'MANG' category.
2025-12-08 Swedish
Cinclus Pharma recruits Magnus Christensen as new CFO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CFO and an interim CFO for Cinclus Pharma. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2025-12-08 English
Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is a formal 'Notice of Extraordinary General Meeting' for Cinclus Pharma Holding AB. It provides details on the meeting date, location, participation procedures (including proxy and postal voting), the proposed agenda, and nomination committee proposals. While it contains information about the meeting, it is a solicitation document sent to shareholders to inform them of the upcoming meeting and request their participation/votes. According to the filing definitions, this falls under 'Proxy Solicitation & Information Statement' (PSI).
2025-12-08 English
Kallelse till extra bolagsstämma i Cinclus Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is a formal 'Kallelse till extra bolagsstämma' (Notice of Extraordinary General Meeting) for Cinclus Pharma Holding AB. It contains the agenda, voting procedures, and proposals for the meeting. While it provides information for shareholders, it is a solicitation document sent prior to the meeting to request participation and votes. According to the provided definitions, this falls under 'Proxy Solicitation & Information Statement' (PSI), as it serves to inform shareholders and request their participation/votes for an upcoming meeting.
2025-12-08 Swedish
Cinclus Pharmas valberedning föreslår ny representant för bolagets grundare till styrelsen
Board/Management Information Classification · 100% confidence The document is an announcement regarding a proposed change in the company's board of directors, specifically the nomination of a new board member to replace an outgoing one. This falls under the category of board or management information. Although it mentions an upcoming extraordinary general meeting, the primary purpose of the text is to announce the board change proposal, not to provide the meeting materials themselves.
2025-12-01 Swedish

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.